Clarus Re-submits JATENZO NDA Following Positive Results of inTUne Trial
26. Juni 2017 08:30 ET
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., June 26, 2017 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced the re-submission of its New Drug Application (NDA) for JATENZO™ (formerly Rextoro™), the Company’s...
Clarus Therapeutics Provides Update on Patent Infringement Lawsuit Against Lipocine’s Oral Product for Testosterone Replacement Therapy
13. Oktober 2016 08:30 ET
|
Clarus Therapeutics, Inc.
Court dismissed lawsuit due to lack of FDA approval for LPCN-1021 and not on merits of case Clarus will be allowed to refile its lawsuit, if necessary NORTHBROOK, Ill., Oct. 13, 2016 (GLOBE...
Clarus Therapeutics Initiates Phase 3 Clinical Trial of Oral Testosterone Replacement Therapy
17. Mai 2016 08:30 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., May 17, 2016 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., a men’s health specialty pharmaceutical company focused on the development and commercialization of JATENZOTM, its...
Clarus Therapeutics Submits New Drug Application for Rextoro (formerly CLR-610) for the treatment of Low Testosterone
13. Januar 2014 09:00 ET
|
Clarus Therapeutics Holdings, Inc.
Northbrook, Ill, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Clarus
Therapeutics, Inc., today announced the submission of a New
Drug Application (NDA) for Rextoro™ (formerly CLR-610), the
Company's oral...
Clarus Therapeutics Presents at 32nd Annual J.P. Morgan Healthcare Conference
09. Januar 2014 10:00 ET
|
Clarus Therapeutics Holdings, Inc.
Northbrook, Ill, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Clarus
Therapeutics, Inc., today announced that Robert E. Dudley,
Ph.D., chief executive officer of Clarus Therapeutics will present
an update on the...
Clarus Therapeutics Bolsters Executive Team with Addition of Chief Medical and Chief Scientific Officers
01. Juli 2013 08:00 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, July 1, 2013 (GLOBE NEWSWIRE) -- Clarus
Therapeutics, Inc., today announced the hiring of Theodore M.
Danoff, M.D., Ph.D. and Wael A. Salameh, M.D., FACP to fill the
newly created...
Clarus Therapeutics Top-line Results Show Oral Testosterone Replacement Candidate, CLR-610, Meets Phase 3 Study Primary Efficacy Endpoint
25. September 2012 08:00 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, Sept. 25, 2012 (GLOBE NEWSWIRE) -- Clarus
Therapeutics, Inc., today reported top-line results from the
Company's ongoing Phase 3 study of
CLR-610, the Company's proprietary oral...
Clarus Therapeutics Strengthens Patent Estate with Issuance of a U.S. Patent Directed to Formulations and Method of Use of Clarus' Oral Testosterone Product
19. September 2012 08:00 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics,
Inc., today announced that the U.S. Patent and Trademark Office
issued U.S. Patent No. 8,241,664 entitled, "Pharmaceutical...
Clarus Therapeutics Appoints Bela S. Denes, M.D. as Chief Medical Officer
21. Juni 2012 08:00 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, June 21, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced the appointment of
Bela S. Denes, M.D. to the newly created role of chief medical
officer. Dr. Denes was...
Clarus Therapeutics Completes Patient Enrollment in Phase 3 Study of its Proprietary Oral Testosterone Replacement Therapy
01. Mai 2012 08:22 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, May 1, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics,
Inc., today announced that patient enrollment has been
completed in the Company's pivotal Phase 3 clinical trial of...